To the Editor,
I read with great interest the study by Kuroshima et al. [1], which combined nucleus pulposus cell experiments with a rat-tail compression model to examine the selective transient receptor potential vanilloid 4 (TRPV4) agonist GSK1016790A in intervertebral disc degeneration. The concordant improvements in extracellular matrix markers, apoptosis, senescence, disc height, and histomorphology provide important gain-of-function evidence that carefully titrated TRPV4 activation may support disc homeostasis. The mechanistic interpretation, however, should be considered in light of the context-dependent nature of TRPV4 signaling. TRPV4 inhibition has reduced disc injury during hyperphysiological compression and sustained loading [2,3]. whereas agonist activation in the present study enhanced matrix synthesis and disc preservation [1]. This apparent bidirectionality makes confirmation of functional autophagy and pathway dependence particularly important.
The authors interpreted increased LC3-II and decreased sequestosome 1 (p62/SQSTM1) expression as enhanced autophagy [1]. However, LC3-II abundance at a single time point reflects the balance between autophagosome formation and lysosomal clearance and may increase during either accelerated flux or impaired degradation. p62/SQSTM1 is also influenced by transcriptional and nonautophagic mechanisms. The current autophagy guidelines therefore favor turnover-based assessment over static markers alone [4]. In the nucleus pulposus cell system, comparison of GSK1016790A treatment with and without bafilomycin A1 or chloroquine, together with a tandem mCherry-GFP-LC3 reporter, could determine whether TRPV4 activation produces effective autophagosome-to-lysosome processing. This focused in vitro approach is feasible and is supported by prior disc-cell experiments using autophagy-related gene 5 (ATG5) knockdown and chloroquine [5]. Equivalent flux testing in the rat-tail model would be substantially more demanding and should be viewed as a longer-term extension rather than a prerequisite for interpreting the current study.
related issue is pathway necessity. The observed calcium influx, adenosine monophosphate-activated protein kinase (AMPK) phosphorylation, mechanistic target of rapamycin (mTOR)/70-kDa ribosomal protein S6 kinase suppression, and extracellular matrix preservation form a biologically coherent sequence but remain associative within the agonist-treated model. The authors’ previous TRPV4-knockdown study already provides valuable partial loss-of-function support [6]. A proportionate next step would therefore be a focused in vitro epistasis experiment combining GSK1016790A with TRPV4 antagonism, AMPK inhibition or knockdown, or suppression of ATG5 or ATG7. Loss of the observed preservation of COL2A1 and aggrecan under these conditions would more directly establish dependence on the proposed TRPV4-AMPK/mTOR-autophagy axis without requiring replication of every intervention in vivo.
For spine surgeons, this distinction has practical translational implications. Any future intradiscal use of a calcium-mobilizing TRPV4 agonist would require a safe dosing window that accounts for dose, exposure duration, degeneration stage, and mechanical loading environment. Demonstrating productive autophagic flux and pathway dependence would help distinguish adaptive mechanotransduction from calcium-mediated injury and could inform both treatment dosing and selection of discs most likely to benefit.
These considerations do not diminish the importance of this elegant study. Rather, they clarify realistic next experiments that could advance TRPV4 agonism from a promising biological association toward a causally validated and clinically translatable strategy for intervertebral disc degeneration.
Footnotes
Conflict of Interest
The author has nothing to disclose.
REFERENCES
- 1.Kuroshima K, Takeoka Y, Yurube T, et al. Agonist-induced activation of transient receptor potential vanilloid 4 promotes autophagy and extracellular matrix synthesis in the rat intervertebral disc. Neurospine. 2026;23:347–64. doi: 10.14245/ns.2551582.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Cambria E, Heusser S, Scheuren AC, et al. TRPV4 mediates cell damage induced by hyperphysiological compression and regulates COX2/PGE2 in intervertebral discs. JOR Spine. 2021;4:e1149. doi: 10.1002/jsp2.1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Easson GWD, Savadipour A, Anandarajah A, et al. Modulation of TRPV4 protects against degeneration induced by sustained loading and promotes matrix synthesis in the intervertebral disc. FASEB J. 2023;37:e22714. doi: 10.1096/fj.202201388R. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) Autophagy. 2021;17:1–382. doi: 10.1080/15548627.2020.1797280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ito M, Yurube T, Kanda Y, et al. Inhibition of autophagy at different stages by ATG5 knockdown and chloroquine supplementation enhances consistent human disc cellular apoptosis and senescence induction rather than extracellular matrix catabolism. Int J Mol Sci. 2021;22:3965. doi: 10.3390/ijms22083965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Matsuo T, Takeoka Y, Yurube T, et al. Transient receptor potential vanilloid 4 knockdown decreases extracellular matrix synthesis via autophagy suppression in the rat intervertebral disc. JOR Spine. 2025;8:e70046. doi: 10.1002/jsp2.70046. [DOI] [PMC free article] [PubMed] [Google Scholar]
